Palivizumab biosimilar (mAbxience)
帕利珠单抗生物类似药（mAbxience）
Report date: 2025/05/06 11:11:58
Base Information
Drug NamePalivizumab biosimilar (mAbxience)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMabxience Sa
China Registration ClassN/A
Develop Information
Active CompaniesMabxience Research SL
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A